HER-2 POSITIVE BREAST CANCER
Clinical trials for HER-2 POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER-2 POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER-2 POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Smart combo therapy aims to boost remission in HER2+ breast cancer
Disease control Not yet recruitingThis study tests a new combination of drugs (PLD, cyclophosphamide, trastuzumab, and pertuzumab) for people with HER2-positive early breast cancer who still have cancer after initial treatment. The goal is to see if this combo can increase the rate of complete remission before su…
Matched conditions: HER-2 POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:03 UTC
-
New MRI dye could spot brain tumors sooner in lung, breast, and skin cancer patients
Diagnosis Not yet recruitingThis study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Early detection may offer more treatment options and prevent neurological symptoms. Participants …
Matched conditions: HER-2 POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 16, 2026 12:54 UTC
-
Gut check: can your microbiome predict verzenio side effects?
Knowledge-focused Not yet recruitingThis study looks at how the bacteria in your gut change when you take Verzenio (abemaciclib) for breast cancer. The drug can cause diarrhea and other stomach issues, and researchers want to see if these changes in gut bacteria are linked to those side effects. About 12 people wit…
Matched conditions: HER-2 POSITIVE BREAST CANCER
Phase: NA • Sponsor: University of Vermont Medical Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:04 UTC